Study Funded by National Pharmaceutical Council Determines PGx May Yield Big Returns for Drugmakers

A recent study found that pharmacogenomics could shorten drug-development timelines and thus provide firms with greater earnings from expanded patent exclusivity periods. The report also outlines various pricing models that would allow drug companies to compensate for the smaller market size of personalized drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.